Last reviewed · How we verify

Aripiprazole depot 25 or 50 mg

Otsuka Pharmaceutical Development & Commercialization, Inc. · Phase 3 active Small molecule Quality 3/100

Aripiprazole depot 25 or 50 mg is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc.. It is currently in Phase 3 development. Also known as: Abilify.

At a glance

Generic nameAripiprazole depot 25 or 50 mg
Also known asAbilify
SponsorOtsuka Pharmaceutical Development & Commercialization, Inc.
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Aripiprazole depot 25 or 50 mg

What is Aripiprazole depot 25 or 50 mg?

Aripiprazole depot 25 or 50 mg is a Small molecule drug developed by Otsuka Pharmaceutical Development & Commercialization, Inc..

Who makes Aripiprazole depot 25 or 50 mg?

Aripiprazole depot 25 or 50 mg is developed by Otsuka Pharmaceutical Development & Commercialization, Inc. (see full Otsuka Pharmaceutical Development & Commercialization, Inc. pipeline at /company/otsuka-pharmaceutical-development-commercialization-inc).

Is Aripiprazole depot 25 or 50 mg also known as anything else?

Aripiprazole depot 25 or 50 mg is also known as Abilify.

What development phase is Aripiprazole depot 25 or 50 mg in?

Aripiprazole depot 25 or 50 mg is in Phase 3.

Related